Results 41 to 50 of about 80,027 (384)
Angiotensin II Receptor Antagonists and Hypertension
Clinical and Experimental Hypertension, 1999 Over recent years, a number of imidazole derivatives that specifically bind to the angiotensin II type 1 receptor, thereafter called sartans, have been developed and made available to the clinician. Whether targeting antihypertensive treatment with such a high specificity within the renin cascade may carry major clinical advantage over inhibiting ...
Jean Ribstein +2 more
openaire +2 more sources
В мире научных открытий, 2016 The article discusses the effectiveness of 3-month therapy with angiotensin converting enzyme inhibitors fosinopril receptor and antagonists of the angiotensin II valsartan to achieve target BP(
Zarina Vyacheslavovna Bitarovа +3 more
doaj +1 more source
Anatolian Journal of Cardiology, 2023 Background: The risk of cardiovascular disease is correlated with the frequency and control of associated risk factors in diabetes mellitus and may vary according to country.
Aytekin Oğuz +10 more
doaj +1 more source
Is Covid-19 severity associated with ACE2 degradation? [PDF]
arXiv, 2021 Covid-19 is particularly mild with children, and its severity escalates with age. Several theories have been proposed to explain these facts. In particular, it was proposed that the lower expression of the viral receptor ACE2 in children protects them from severe Covid.
arxiv
The Use of Dried Blood Spots for the Quantification of Antihypertensive Drugs
International Journal of Analytical Chemistry, 2018 Hypertension or high blood pressure is a harbinger of cardiovascular diseases. There are several classes of drugs used to treat hypertension. This review discusses the use of dried blood spots (DBSs) for the quantification by mass spectrometry (MS ...
Alexander Chernonosov
doaj +1 more source
Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats. [PDF]
PLoS ONE, 2012 Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are the standard clinical therapy of diabetic nephropathy (DN), while aldosterone antagonists are only used as adjuncts.
Nora F Banki +15 more
doaj +1 more source
Label-free cell signaling pathway deconvolution of Angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIII\IV responses [PDF]
Pharmacol Res, 136:108-20 (2018), 2019 Angiotensin II (AngII) type 1 receptor (AT1R) is a G protein-coupled receptor known for its role in numerous physiological processes and its implication in many vascular diseases. Its functions are mediated through G protein dependent and independent signaling pathways. AT1R has several endogenous peptidic agonists, all derived from angiotensinogen, as
arxiv +1 more source
Antidepressant-like Effects of Neuropeptide SF (NPSF) [PDF]
World Journal of Research and Review (WJRR) ISSN:2455-3956,
Volume-4, Issue-5, May 2017 Pages 26-30, 2020 Neuropeptide SF (NPSF) is a member of RFamide neuropeptides that play diverse roles in central nervous system. Little is know about the effects of NPSF on brain functions. Antidepressant-like effect of NPSF was studied in modified mice FST. NPSF showed the antidepressant-like effects by decreasing the immobility time and increasing the climbing and ...
arxiv
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source
Kidney Research and Clinical Practice, 2018 Background: Previous studies have shown that aldosterone antagonists have a proteinuria-lowering effect in patients with proteinuria and progressive proteinuric disease not adequately controlled by the use of angiotensin receptor blockers (ARBs ...
Byung Chul Yu +6 more
doaj +1 more source